1. Home
  2. AGIO vs PSEC Comparison

AGIO vs PSEC Comparison

Compare AGIO & PSEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$28.65

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Prospect Capital Corporation

PSEC

Prospect Capital Corporation

HOLD

Current Price

$2.89

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
PSEC
Founded
2007
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2013
2004

Fundamental Metrics

Financial Performance
Metric
AGIO
PSEC
Price
$28.65
$2.89
Analyst Decision
Buy
Sell
Analyst Count
8
1
Target Price
$36.25
$2.50
AVG Volume (30 Days)
1.3M
4.6M
Earning Date
02-12-2026
02-09-2026
Dividend Yield
N/A
18.88%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$44,791,000.00
$680,752,000.00
Revenue This Year
$27.83
N/A
Revenue Next Year
$134.79
N/A
P/E Ratio
N/A
N/A
Revenue Growth
36.26
N/A
52 Week Low
$22.24
$2.45
52 Week High
$46.00
$4.47

Technical Indicators

Market Signals
Indicator
AGIO
PSEC
Relative Strength Index (RSI) 52.75 62.18
Support Level $26.25 $2.76
Resistance Level $28.87 $3.00
Average True Range (ATR) 1.09 0.09
MACD 0.25 0.01
Stochastic Oscillator 74.29 71.05

Price Performance

Historical Comparison
AGIO
PSEC

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About PSEC Prospect Capital Corporation

Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.

Share on Social Networks: